Aramchol arachidyl amino cholanoic acid: Phase IIa started

GalMed began a double-blind, placebo-controlled, Israeli Phase IIa trial to evaluate once-daily 100 or 300 mg oral Aramchol for 3 months in 60 patients with non-alcoholic fatty liver disease, includin...